March 20th 2025
A new study finds that postmenopausal women with a reduced creatinine-to-cystatin C ratio experience decreased muscle volume and slower walking speed, highlighting its role as a potential biomarker for muscle health.
Satellite Symposia at the 2025 Oncology Nursing Society Congress
April 11-12, 2025
Register Now!
16th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™
May 3, 2025
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Burst CME™: The Patient Journey – Unmet Needs From Diagnosis Through Management of Migraine
View More
Burst CME™: Setting the Stage – Individualizing Migraine Care for Diverse Populations Across Care Settings
View More
Burst CME™: Optimizing the Use of CGRP Targeted Agents for the Treatment of Migraine
View More
Burst CME™: Optimizing Migraine Management – Addressing Unmet Needs, Individualizing Care for Diverse Populations, and Utilizing CGRP Targeted Agents
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances
View More
Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer
View More
Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care
View More
Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials
View More
Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations
View More
Expert Illustrations and Commentaries™: Visualizing Glucocorticoid Receptor Modulation in Platinum-Resistant Ovarian Cancer—Looking at Novel Pathways With an Eye Toward the Future of Treatment
View More
Transdermal Contraception: Contraception Patch. Interview with Ronald T. Burkman, MD
“We just heard a presentation about one of the several new devices for contraception and you took part in a lot of research about this Transdermal Patches for contraception.
Read More
To Sleep, Perchance To Dream: Recognizing and Addressing Menopause-Related Sleep Disruption
November 9th 2011Hormone fluctuations. Hot flashes and night sweats. Depression and changes in mood. Coincidental and age-related changes in health and social issues. All of these factors associated with menopause can affect a patient’s sleep quality.
Read More
Bioidentical Hormones: Advances in Research and What to Ask Your Provider
November 7th 2011One of the earliest uses of HRT was documented in an 1897 publication highlighting the use of desiccated ovarian extracts to alleviate vasomotor symptoms. As science evolved, publications emerged describing the extraction of hormones from pregnant female urine (Emmenin®) in 1934 and eventually pregnant mare urine (Premarin®) in 1937 for the therapeutic relief of menopausal symptoms.
Read More
Despite the positive effects of hormone replacement therapy for treating menopause-related issues, HRT’s association with negative adverse outcomes has cast a dark shadow on it. Now, new research out of Europe shows that HRT also increases severe asthma attacks in patients.
Read More
Advances in the Prevention and Management of Osteoporosis New Clinical Insights
October 14th 2011During the past decade, research into postmenopausal osteoporosis has led to a heightened understanding of the disease process. Awareness of current diagnostic guidelines, prevention strategies, and treatment options is key to the successful management of this condition.
Read More
HRT May Prevent Fractures in Postmenopausal Women Without Adverse Side Effects
October 14th 2011Researchers at the Rush Center for Clinical Studies at Rush-Presbyterian-St. Luke’s Medical Center in Chicago will investigate whether the hormone replacement therapy tibolone prevents spinal fractures in osteoporotic postmenopausal women.
Read More
Bone Densitometry as a Screening Tool for Osteoporosis in Postmenopausal Women
October 14th 2011Osteoporosis is a degenerative bone disease that affects approximately 24 million Americans. Of these, 33 percent are postmenopausal women who have decreased bone density due to lowered estrogen levels.
Read More
Osteoporosis is a decrease in bone mass and strength causing susceptibility to fractures. It is the major cause of bone fractures in postmenopausal women and older persons in general. Osteoporosis has no clear beginning, and until recently its first visible sign was a debilitating fracture of the hip, wrist, or vertebral bodies causing pain or deformity.
Read More
AACE Clinical Practice Guidelines for the Prevention and Treatment of Postmenopausal Osteoporosis
October 13th 2011In this era of constrained health-care resources, a critical need exists for efficient, measurable systems of disease management that strike a balance between social responsibility and patient welfare.
Read More
Assessing Bone Resorption Levels to Predict Skeletal Responses to HRT
October 13th 2011Osteoporosis is recognized as a significant contributor to morbidity and mortality in postmenopausal women. Several effective strategies, including calcium supplementation, weight-bearing exercise, and, most importantly, hormone replacement, have been developed to prevent or at least delay clinically significant bone loss.
Read More
Thyroid Dysfunctional State Detected by QUS Measurements at Multiple Skeletal Sites
October 13th 2011Hyperthyroidism in postmenopausal women is associated with accelerated bone loss that results in lower BMD as detected by DEXA, SPA, QCT as well as bone markers’ levels. However, there is no data of QUS evaluation in thyrotoxic patients.
Read More
"Doctor, just what is a hot flash?"
October 7th 2011Hot flashes, hot flushes, power surges-- they go by a variety of names and are one of the most common symptoms of the perimenopause and menopause. Often a premenopausal woman will ask, "how will I know if I am having hot flashes"? This can be compared to the question a woman who has never had a baby asks, "how I will know if it's really a contraction"? If a woman is having significant hot flashes, she will not have to ask!
Read More
"Doctor, is the patch better, and how do I use it?"
October 7th 2011The benefits of using the patch for hormone replacement, with a few exceptions, are not significantly different from those when taken in a pill form. The choice should depend primarily upon the woman's preference, and for those choosing the patch there are a few small tricks for making it easier to use.
Read More
Staying Smart with Estrogen: Estrogen Replacement and Mental Functioning
October 7th 2011Losing your keys? Losing your patience? Losing your mind? If you are a midlife woman having difficulties, the solution may be increasing your estrogen level. More and more research studies are showing beneficial effects of hormone replacement on mental functioning. Women taking estrogen showed increased brain activation and reinstated patterns observed in younger subjects performing memory tasks, according to a recent study.
Read More
The Significance of Bleeding after Menopause
October 7th 2011Bleeding after menopause or "postmenopausal bleeding" ("PMB") can be defined as the resumption of vaginal bleeding at least 6 months after a woman experiences her last menstrual period. This assumes of course that she is indeed menopausal ie. in her late 40's, perhaps having hot flashes and night sweats, mood swings, insomnia, perhaps experiencing some vaginal dryness.
Read More
Theories of Fibroid Information
October 3rd 2011Despite the major public health impact of leiomyomas, little is known about their cause. Until recently, the steroid hormones estrogen and progesterone were considered the most important regulators of leiomyoma growth. There is abundant evidence that estrogen promotes fibroid growth including the clinical observations that fibroids grow in the presence of high levels of estrogen, such as during the reproductive years, and that they regress in the presence of low levels of estrogen, such as following menopause or during gonadotropin releasing hormone (GnRH) agonist therapy.
Read More
Is HRT still indicated for the primary prevention of osteoporosis?
October 2nd 2011Hormone Replacement Therapy: In most European countries, the actual Guideline on the Evaluation of New Medicinal Products in the Treatment of Primary Osteoporosis is incomplete in that, unlike the previous Note for Guidance on Postmenopausal Osteoporosis in Women (EMEA 2001 Guidance), it fails to address the prevention of osteoporosis indication.
Read More
Climacterium and the menopause
October 2nd 2011The world of menopausal care is changing. For many years, the scientific community involved in menopause research has been amassing evidence that the menopause is associated with multiple complaints and chronic diseases, and that postmenopausal hormone therapy has the potential to prevent or treat most of them.
Read More
Aging, Not Menopause, Linked to Increased Risk of Heart Disease
September 30th 2011Hormonal changes associated with menopause do not increase a woman’s risk for heart disease and heart disease mortality, according to new research published in BMJ. The work of Dr Dhananjay Vaidya, assistant professor of medicine at John Hopkins School of Medicine, and colleagues contradict the previously hypothesis that heart disease and heart attacks rise dramatically after menopause.
Read More
Venous Thromboembolism and Estrogen Hormone Therapy: Patch Presents Less Risk Than Pill
September 25th 2011A new study provides a real-world snapshot of risks associated with venous thromboembolism in women receiving hormone replacement therapy, demonstrating that women who use an estradiol transdermal system may have less risk of developing thromboembolism than their counterparts who receive oral estrogen-only hormone therapy agents.
Read More
FDA Bounces Request to Approve Desvenlafaxine (Pristiq) for Menopause
September 21st 2011Pfizer Inc. reports that it has received a "complete response letter" from the Food and Drug Administration (FDA) denying its application to approve desvenlafaxine (Pristiq) for moderate to severe vasomotor symptoms of menopause such as hot flashes.
Read More
Poll: How Are You Managing Women With Sleep Disturbances Who Have Discontinued Hormone Therapy?
September 13th 2011A recent study on sleep disturbances in menopause shows a direct connection to the use of hormone therapy. Specifically, when women stop taking hormone therapy they experienced greater periods of poor sleep, waking up during the night, difficulty falling asleep, waking up to early and not feeling rested.
Read More
Popular Herbal Supplement Shows Promise in Treating Menopausal Sleep Disturbances
September 13th 2011According to results from a new study, a popular herbal remedy may come to the rescue of women suffering from postmenopausal sleep disturbances. About half of postmenopausal women experience some degree of sleep disturbance, which in turn impacts their quality of life.
Read More